Premium
Novel molecular pathways in Gorham disease: Implications for treatment
Author(s) -
Hagendoorn Jeroen,
Yock Torunn I.,
Borel Rinkes Inne H.M.,
Padera Timothy P.,
Ebb David H.
Publication year - 2014
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.24832
Subject(s) - medicine , disease , medline , computational biology , bioinformatics , intensive care medicine , pathology , political science , law , biology
Rapid advances in evidence‐based treatment schedules are a hallmark of modern oncology. In rare neoplastic diseases, however, clinical expertise is hard to build and evidence based on randomized trials almost impossible to collect. Gorham disease is a rare form of lymphatic proliferation accompanied by osteolysis, which usually occurs in young adults. Despite the fact that the clinical course of Gorham disease is often devastating and occasionally fatal, insights into its biological background are sparse and standardized treatment unavailable. Interestingly, recent knowledge on the mechanisms of lymphangiogenesis may help elucidate the pathophysiology of Gorham disease and lead to novel treatment targets. Here, we discuss our current understanding of Gorham disease, discuss established and emerging therapeutic strategies, and attempt to frame a treatment rationale. Pediatr Blood Cancer 2014;61:401–406. © 2013 Wiley Periodicals, Inc.